Literature DB >> 1622187

Absolute bioavailability of cefprozil after oral administration in beagles.

R H Barbhaiya1, L Wang, W C Shyu, K A Pittman.   

Abstract

The absolute bioavailability of cefprozil, a new oral cephalosporin, in four beagles was evaluated. In this two-way crossover study, each dog received a 125-mg dose of cefprozil either as an oral aqueous solution or as a 15-min intravenous infusion. A high-performance liquid chromatographic assay with UV detection was employed for the determination of cefprozil concentrations in plasma and urine. Key pharmacokinetic parameters were calculated by noncompartmental methods. Cefprozil was well absorbed after oral administration, and peak concentrations of 17.6 to 26.6 micrograms/ml were attained at 60 min after drug administration. The apparent elimination half-life of cefprozil was about 70 min. The renal clearance was about 60% of total body clearance and is suggestive of significant nonrenal clearance. The absolute bioavailability of cefprozil ranged from 67.1 to 79.1% in the dogs.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1622187      PMCID: PMC190583          DOI: 10.1128/AAC.36.3.687

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

Review 1.  Pharmacokinetics and clinical use of cephalosporin antibiotics.

Authors:  C H Nightingale; D S Greene; R Quintiliani
Journal:  J Pharm Sci       Date:  1975-12       Impact factor: 3.534

2.  Phase I study of multiple-dose cefprozil and comparison with cefaclor.

Authors:  R H Barbhaiya; U A Shukla; C R Gleason; W C Shyu; R B Wilber; R R Martin; K A Pittman
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

3.  Comparison of cefprozil and cefaclor pharmacokinetics and tissue penetration.

Authors:  R H Barbhaiya; U A Shukla; C R Gleason; W C Shyu; R B Wilber; K A Pittman
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

4.  Phase I study of single-dose BMY-28100, a new oral cephalosporin.

Authors:  R H Barbhaiya; C R Gleason; W C Shyu; R B Wilber; R R Martin; K A Pittman
Journal:  Antimicrob Agents Chemother       Date:  1990-02       Impact factor: 5.191

5.  Comparative antibacterial activity of a new oral cephalosporin, BMY-28100.

Authors:  N X Chin; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1987-03       Impact factor: 5.191

6.  The application of statistical moment theory to the evaluation of in vivo dissolution time and absorption time.

Authors:  S Riegelman; P Collier
Journal:  J Pharmacokinet Biopharm       Date:  1980-10

7.  Comparative pharmacokinetics of cephalexin, cefaclor, cefadroxil, and CGP 9000.

Authors:  H Lode; R Stahlmann; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1979-07       Impact factor: 5.191

8.  The pharmacokinetics of the oral cephalosporins cefaclor, cephradine and cephalexin.

Authors:  P G Welling; S Dean; A Selen; M J Kendall; R Wise
Journal:  Int J Clin Pharmacol Biopharm       Date:  1979-09

9.  BMY 28100, a new oral cephalosporin.

Authors:  F Leitner; T A Pursiano; R E Buck; Y H Tsai; D R Chisholm; M Misiek; J V Desiderio; R E Kessler
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

10.  Human intravenous pharmacokinetics and absolute oral bioavailability of cefatrizine.

Authors:  M Pfeffer; R C Gaver; J Ximenez
Journal:  Antimicrob Agents Chemother       Date:  1983-12       Impact factor: 5.191

  10 in total
  1 in total

Review 1.  Examination of Urinary Excretion of Unchanged Drug in Humans and Preclinical Animal Models: Increasing the Predictability of Poor Metabolism in Humans.

Authors:  Nadia O Bamfo; Chelsea Hosey-Cojocari; Leslie Z Benet; Connie M Remsberg
Journal:  Pharm Res       Date:  2021-07-12       Impact factor: 4.580

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.